Biophytis S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPTS research report →
Range $15 – $15
Price Chart
About the company
Biophytis S. A. operates as a clinical-stage biotechnology firm dedicated to advancing therapeutic solutions aimed at decelerating degenerative processes and enhancing functional outcomes for individuals grappling with age-related illnesses.
- CEO
- Stanislas Veillet
- IPO
- 2021
- Employees
- 22
- HQ
- Paris, FR
Get TickerSpark's AI analysis on BPTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.61M
- P/E
- -0.06
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.07
- EV/EBITDA
- -1.54
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 153.48%
- ROIC
- -2242.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-803,000-65.9%
- Op Income
- $-14,333,000
- Net Income
- $-17,026,000+29.7%
- EPS
- $-12.55+77.6%
- OCF Growth
- +32.2%
- FCF Growth
- +31.6%
- 52W High
- $168.80
- 52W Low
- $8.05
- 50D MA
- $16.44
- 200D MA
- $35.77
- Beta
- 1.05
- RSI (14)
- 35
- Avg Volume
- 9.04K
No earnings-call transcripts are available for BPTS yet.
- Free Float
- 350095.2%
- Shares Outstanding
- 317.35K
- Float Shares
- 1.11B
of shares held by institutions
5 13F filers
Our BPTS coverage
Recent articles, reports, and earnings notes.
No research on BPTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BPTS report →Biophytis Targets Mobility Restoration in Patients with Obesity
newsfilecorp.com · Apr 22
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
newsfilecorp.com · Apr 9
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity
newsfilecorp.com · Mar 24
Biophytis Revolutionizes Sarcopenia
newsfilecorp.com · Mar 17
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
newsfilecorp.com · Feb 25
Biophytis Unveils Its Outlook Strategies for 2025
newsfilecorp.com · Feb 11
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
newsfilecorp.com · Jan 27
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
newsfilecorp.com · Jan 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.